MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Canada to buy 7.6M BD rapid COVID-19 tests

Canada to buy 7.6M BD rapid COVID-19 tests

By

Becton DickinsonBecton Dickinson (NYSE:BDX) announced that Health Canada authorized its rapid COVID-19 tests and will buy 7.6 million of them.

Under interim order, Health Canada authorized BD’s rapid, point-of-care SARS-CoV-2 antigen test for use with the BD Veritor Plus system. The order for 7.6 million tests runs through March 2021 in an effort to support Canada’s planning for an advanced COVID-19 testing strategy, according to a news release.

“The Government of Canada continues to work diligently to provide Canadians with access to effective and efficient COVID-19 testing solutions,” Canada Minister of Public Services and Procurement Anita Anand said in the release. “This new agreement with BD is critical to assisting the provinces and territories in their respective efforts to reduce the spread of the virus. We will continue to support Canadians through the COVID-19 pandemic.”

BD touts its test as capable of delivering results in approximately 15 minutes at the point-of-care. Health Canada authorized the test in early October, while it has been available in the U.S. under emergency use authorization (EUA) since July.

“As the demands for SARS-CoV-2 testing are increasing in Canada, we are excited to bring another testing solution to the Canadian market,” BD Canada president Greg Miziolek said in the release. “The ability to perform SARS-CoV-2 testing at the point-of-care and deliver results while the patient waits will be truly impactful to help relieve some of the pressures on the testing labs and quickly identify affected patients. We applaud the federal government for their proactive approach in planning for future needs with a centralized order for antigen detection tests.

“We look forward to partnering with Canada’s provincial health authorities to optimize the deployment of the BD Veritor Plus System to meet regional and local public health needs.”

The test has come under scrutiny for its use in the U.S., with reports of false-positive results in September, followed by further reports earlier this week claiming that BD’s antigen test was among those distributed to nursing homes but going unused due to fears over accuracy.

A BD spokesperson told MassDevice that the September reports did not reflect the proven accuracy of BD’s tests on the Veritor Plus system in clinical trials, while the company told The Wall Street Journal earlier this week that testing plays an “essential role” in stopping the spread of COVID-19 and that it has continued to receive regular reorders of its tests from nursing homes.

In case you missed it

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]